ArticleFrontiers in endocrinology2026
Thyroid feedback quantile-based index predicts 90-day all-cause mortality or readmission in hospitalized heart failure patients: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Thyroid Feedback Quantile-Based Index (TFQI), a recently developed indicator derived from thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels, has demonstrated prognostic value in metabolic diseases. Nevertheless, its utility in predicting clinical endpoints among heart failure (HF) patients remains unclear. This study aimed to identify the optimal TFQI cutoff for risk stratification and to evaluate its association with adverse outcomes in HF patients. Methods: A total of 402 HF patients were enrolled in the study. Using the composite outcome of 90-day all-cause mortality or heart failure readmission, the X-tile project determined the optimal TFQI threshold. TFQI's predictive value was then evaluated using univariate and multivariate Cox regression, restricted cubic spline (RCS) analysis, and Kaplan-Meier curves. Results: A threshold of 0.10 best stratified high-risk patients (adjusted HR: 1.95, 95% CI: 1.11-3.43, P = 0.019). RCS analysis indicated a linear dose-response (P for non-linearity = 0.677). Kaplan-Meier analysis confirmed significantly worse survival with TFQI > 0.10 vs ≤ 0.10 (Log-rank P = 0.004). Conclusions: A TFQI exceeding 0.10 is associated with a significantly increased risk of 90-day all-cause mortality or HF readmission in hospitalized HF patients. This study suggests TFQI acts as a promising exploratory biomarker correlated with adverse clinical outcomes in HF. Further large-scale, multicenter and prospective studies are still required to verify its clinical value and confirm its role in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.